Research and Markets (http://www.researchandmarkets.com/reports/c92072)
has announced the addition of “Understanding
the Global Pharmaceutical Market” to their
offering.
Although the origins of the modern pharmaceutical industry can be traced
back to the late nineteenth century, the real development started only
in 1960s due to some significant new discoveries with permanent patent
protection. Next couple of decades saw tightening of regulatory control
in the sector all across the world. It was during this period that drugs
got laws for patent protection, leading to the appearance of generic
drugs.
The introduction of generics was very beneficial for society as the
valuable medicines became extremely cheap. 1980s and 1990s saw the
introduction of venture capital in the pharma and biotech industries.
Due to worldwide reforms in the healthcare sector, several regulations
were passed to control the pricing of the drugs and deliverance of
genuine product innovation. By the turn of the century, all the leading
drug companies were spending reasonable amount of their revenue in
research and development (R&D).
Today, the global pharmaceutical industry is more than $550 billion and
has grown at CAGR of more than 6% in last 5 years. Geographically, North
America is the biggest pharmaceutical market with a share of almost 48%,
followed by Europe (30%) and Japan(9%). Around 20% of all retail
prescriptions filled today are related to Medicare Part D, of those,
only 31% are for branded drugs; rest are filled by generics. Oncology is
the fastest-growing sector in pharmaceuticals, driven by the enormous
amount of innovation coming into the market and the enormous unmet need
by patients. The number of drugs available, both to improve and maintain
life, has steadily risen over the last century. At the present time
there are over 1,000 drugs under development, with companies diverting
increasingly large proportions of their revenue streams into R&D, the
primary driver of competitiveness in the industry.
Having traditionally enjoyed strong growth rates, the industry's
operating environment is becomingly increasingly complex. Volume growth
is, currently, negligible, the primary driver of industry value being
rising per-unit values, whilst the rise of generics is eroding sales
growth. Under these circumstances, the global pharmaceutical market is
expected to show slightly slower growth incoming years and is predicted
to be in the range of $735 billion to $745 billion by the end of 2008.
In recent years, pharmaceutical companies in Asia, particularly in
China, South Korea and India, have been a success due to their ability
to retain their cost advantage while matching the quality standards of
the west. Despite an impressive growth, foreign drug makers are
particularly concerned with issues on corruption, governmental
bureaucracy and intellectual property (IP) protection in these
countries. These issues are important particularly when growing drug
counterfeiting activities pose a major global public health risk as well
as a financial and reputation threat to pharmaceutical manufacturers.
Further, there are healthcare concerns especially in Asia, that has the
largest growing number of diabetes patients and WHO’s
studies show that the number of diabetes affected people may grow by
more than 90% over the next 20 years. Drug pricing pressures are
challenging the pharmaceutical industry like never before, with
governments resorting to drug price controls and other measures to
manage spiralling pharmaceutical costs.
Executive Summary 5
Basics of the Industry 6
Industry Definition 6
Lifecycle of a Drug 6
Patent System 6
Drug Lifecycle 7
Drug Discovery 8
Development 10
Industry Cost Structure 11
Types of Costs 11
Pricing and Investment 13
Overview of the Global Pharma Industry 17
Background 17
Industry Analysis 18
Industry Size 18
Industry Segments 20
Geographic Distribution 22
Competitive Analysis 23
Market Outlook 25
Innovations in the Pharma Activities 26
Global Distribution of Activity 26
Innovation in Value Chain 27
Off-Shoring Pharmaceutical Activities 28
Key Markets 31
Profiles of Major Players 60
Abbott Laboratories 60
Astellas Pharma Inc 62
AstraZeneca Plc 63
Australian Pharmaceutical Industries (API) 66
Bayer AG 67
Bayer Schering Pharm 67
Bristol Myers Squibb Co. 68
Cerep SA 69
Cipla Ltd 70
Daewoong Pharmaceutical 70
Dong-A Pharmaceutical 71
Eli Lilly & Co. 72
GlaxoSmithKline Plc. 74
Harbin Pharmaceutical Group 78
Johnson & Johnson 79
Livzon Pharmaceutical Group 80
Merck Group 80
Novartis AG 84
Pfizer Inc. 86
Ranbaxy Laboratories Limited 88
Roche AG 89
Sanofi- Aventis 90
Schering-Plough Corporation 94
Sigma Pharmaceutical Ltd 96
Takeda Pharmaceutical Co 97
Wyeth 98
Appendix and Glossary 100
List of Figures
List of Tables
For more information visit http://www.researchandmarkets.com/reports/c92072.
